Summary of Henry Schein's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Global Sales: $3.5 billion, up 6.7% year-over-year.

Internal Local Currency Sales Growth: 4.6%.

Non-GAAP Operating Income: Increased by 10.5%.

Non-GAAP Earnings Per Share (EPS): Grew 15.5% to $1.27.

GAAP Operating Margin: 4.94%, up 27 basis points from the prior year.

Non-GAAP Operating Margin: 7.21%, up 25 basis points.

Adjusted EBITDA: $288 million, a 12.7% increase from Q2 2025.

Share Repurchases: 2.6 million shares at an average price of $76.69, totaling $200 million.

2Strategic Updates and Business Highlights

Growth Initiatives: Focus on enhancing customer relationships and accelerating growth through technology solutions, particularly the AI-enabled Henry Schein One platform.

Market Position: Strong performance in U.S. dental merchandise, with 8.3% growth, and significant market share gains in Canada.

Technology Growth: Nearly 13,000 customers now subscribe to Dentrix Ascend, with a notable increase in average revenue per customer.

Value Creation Initiatives: Expected to yield at least $200 million in operating income improvements over the next few years, with a focus on operational efficiency and customer satisfaction.

Portfolio Evaluation: Ongoing assessment to prune lower-performing segments and enhance focus on high-growth areas.

3Forward Guidance and Outlook

2026 Sales Growth Guidance: Raised to 4.5% to 5.5%, up from 3% to 5%.

Non-GAAP EPS Guidance: Expected to be in the range of $5.29 to $5.39, reflecting 6% to 8% growth compared to 2025.

Operational Improvements: Anticipated benefits from value creation initiatives expected to ramp up in Q3 and Q4, with a run rate of $125 million in operating income improvements by the end of 2026.

4Bad News, Challenges, or Points of Concern

U.S. Dental Equipment Sales: Declined 1.1% due to tough comparisons from prior year dental school orders, although growth is expected in the second half.

Point-of-Care Diagnostics: Continued lower demand impacting the medical segment, though growth in government-related and Home Solutions businesses is noted.

Remeasurement Gains: Lower than expected, with no further gains anticipated for the remainder of 2026, which may affect EPS growth.

5Notable Q&A Insights

Market Share Gains: Management indicated that growth in the dental consumables market is driven more by market share gains and pricing rather than volume increases.

Value Creation Initiatives: There is confidence in achieving the $200 million target, with a significant portion expected from gross profit initiatives and G&A savings.

Differentiation in Specialty Products: The premium implant segment is performing well in Europe, while the U.S. market is slower, attributed to differing consumer dynamics.

AI Integration: The integration of AI into practice management systems is seen as a key growth driver, enhancing customer engagement and operational efficiency. Overall, Henry Schein's Q2 2026 results reflect strong operational execution and strategic focus, with a positive outlook for the remainder of the year despite some challenges in specific segments.